• 1
    Drug Utilisation Sub-Committee. Item 7.1 Varenicline: review of first 12-months of usage. Department of Health and Ageing: Canberra, October 2009.
  • 2
    Roxon N. New PBS listing for January 2008. Media release NR08/01. Canberra, 1 January 2008.
  • 3
    Drug Utilisation Sub-Committee. Drug Utilisation Database. Department of Health and Ageing: Canberra, 3 March 2010.
  • 4
    Council of Australian Governments. National Partnership Agreement on Preventive Health: Overview. Canberra, 29 November 2009.
  • 5
    Eisenberg M. J., Filion K. B., Yavin D., Bélisle P., Mottillo S., Joseph L. et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Can Med Assoc J 2008; 179: 13544.
  • 6
    Walsh R. A. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev 2008; 27: 52947.
  • 7
    Daubney Garrison G., Dugan S. E. Varenicline: a first line treatment option for smoking cessation. Clin Ther 2009; 31: 46391.
  • 8
    Niaura R., Hays J. T., Jorenby D. E., Leone F. T., Pappas J. E., Reeves K. E. et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008; 24: 193141.
  • 9
    Jorenby D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296: 5663.
  • 10
    Adverse Drug Reactions Advisory Committee. 1. Varenicline: the Australian experience so far. Aust Adverse Drug React Bull 2008; 27: 22.
  • 11
    Hurley S. F., Matthews J. P. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008; 17: 37984.